Of the nine subjects that had a response, six (67%) subjects had a response lasting six months or longer.The trial was conducted at 22 sites in France, United Kingdom, Taiwan, Italy, Canada, Belgium, and the United States.The FDA granted the application for tazemetostat accelerated approval and orphan drug designation. The FDA granted the approval of Tazverik to Epizyme Inc.

References
External links
"Tazemetostat". Drug Information Portal. U.S. National Library of Medicine.
It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped. Overdose
Symptoms
Symptoms are usually due to side effects. Most often encountered are:

Anticholinergic side effects (dry mouth, constipation, paralytic ileus, difficulties in urinating, decreased perspiration)
Coma in severe cases, accompanied by respiratory depression and massive hypotension, shock
Hypotension or hypertension
Rarely, serious ventricular arrhythmia (torsades de pointes), with or without prolonged QT-time
Sedation
Severe extrapyramidal side effects with muscle rigidity and tremors, akathisia, etc. Treatment
Treatment is mostly symptomatic and involves intensive care with stabilization of vital functions. In early detected cases of oral overdose, induction of emesis, gastric lavage, and the use of activated charcoal can be tried. In the case of a severe overdose, antidotes such as bromocriptine or ropinirole may be used to treat the extrapyramidal effects caused by haloperidol, acting as dopamine receptor agonists. ECG and vital signs should be monitored especially for QT prolongation and severe arrhythmias should be treated with antiarrhythmic measures. Prognosis
An overdose of haloperidol can be fatal, but in general the prognosis after overdose is good, provided the person has survived the initial phase. Pharmacology
Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D2 receptor antagonism and slow receptor dissociation kinetics. It has effects similar to the phenothiazines. The drug binds preferentially to D2 and α1 receptors at low dose (ED50 = 0.13 and 0.42 mg/kg, respectively), and 5-HT2 receptors at a higher dose (ED50 = 2.6 mg/kg).